Neta Goldschmidt
Overview
Explore the profile of Neta Goldschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Nachmias B, Godefroy J, Rozenbach E, Ganzel C, Bar-Shalom R, Goldschmidt N, et al.
Clin Nucl Med
. 2020 May;
45(7):542-544.
PMID: 32433173
Residual end of treatment (EOT) FDG-avid lesions are often due to infectious or inflammatory process and not due to refractory lymphoma. Nonetheless, such lesions prompt diagnostic and therapeutic interventions. We...
22.
Herishanu Y, Shaulov A, Fineman R, Basic-Kinda S, Aviv A, Wasik-Szczepanek E, et al.
Am J Hematol
. 2020 Feb;
95(6):604-611.
PMID: 32096887
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression...
23.
Nachmias B, Sandler V, Slyusarevsky E, Pogrebijski G, Kritchevsky S, Ben-Yehuda D, et al.
Ann Hematol
. 2019 Sep;
98(11):2561-2567.
PMID: 31515574
Overt central nervous system (CNS) involvement in aggressive non-Hodgkin's lymphoma (NHL) is rare at diagnosis. Much effort is put to identify risk factors for occult CNS involvement, and the risk...
24.
Perry C, Ben Barouch S, Goldschmidt N, Sarid N, Herishanu Y, Shvidel L, et al.
Am J Hematol
. 2019 Jun;
94(9):992-1001.
PMID: 31211434
The incidence of systemic diffuse large B cell lymphoma (DLBCL) concurrently involving the central nervous system (CNS) at diagnosis, is very low and data regarding the clinical course of these...
25.
Tadmor T, Levy I, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, et al.
Leuk Res
. 2019 Jun;
82:24-28.
PMID: 31152919
Background: Major advances in the treatment of patients with hairy cell leukemia (HCL) have been made following the introduction of purine analogues. The major significant short-term toxicity of cladribine therapy...
26.
Nachmias B, Shaulov A, Lavie D, Goldschmidt N, Gural A, Saban R, et al.
Acta Haematol
. 2019 Apr;
141(4):216-221.
PMID: 30943470
Background: The treatment of relapsed/refractory (R/R) peripheral T cell lymphoma (PTCL) is limited to a few agents. Romidepsin, a histone deacetylase inhibitor, was approved for PTCL treatment as a single...
27.
Goldschmidt N, Horowitz N, Heffes V, Darawshy F, Mashiach T, Shaulov A, et al.
Leuk Lymphoma
. 2019 Jan;
60(8):1890-1898.
PMID: 30689468
Combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is regarded as standard care for diffuse large B-cell lymphoma (DLBCL) and upfront intensification of therapy is still controversial. The current...
28.
Inbar M, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, et al.
Anticancer Res
. 2018 Nov;
38(11):6423-6429.
PMID: 30396967
Background/aim: In this retrospective study, we summarized the national Israeli experience with hairy cell leukemia (HCL) in a large cohort of patients with a long follow-up. Patients And Methods: Demographic...
29.
Gentile M, Shanafelt T, Mauro F, Reda G, Rossi D, Laurenti L, et al.
Eur J Haematol
. 2018 Jul;
PMID: 30039576
No abstract available.
30.
Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, et al.
Eur J Haematol
. 2018 Jun;
101(3):399-406.
PMID: 29949186
Objective: To evaluate disease characteristics and long-term outcomes in patients requiring second-line treatment following fludarabine, cyclophosphamide, and rituximab (FCR), for relapsed/refractory disease (R/R), or following discontinuation due to toxicities. Method:...